Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. [electronic resource]
Producer: 20150603Description: 961-7 p. digitalISSN:- 1879-355X
- Antineoplastic Agents, Alkylating -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Brain Neoplasms -- mortality
- Chemoradiotherapy -- adverse effects
- Dacarbazine -- administration & dosage
- Disease-Free Survival
- Dose Fractionation, Radiation
- Female
- Glioblastoma -- mortality
- Humans
- Male
- Maximum Tolerated Dose
- Metalloporphyrins -- administration & dosage
- Multivariate Analysis
- Supratentorial Neoplasms -- mortality
- Temozolomide
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.